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ABSTRACT 
Benzodiazepines (BZDs) constitute the most widely used symptomatic treatment of insomnia 
and anxiety. Many of these drugs are associated with adverse effects, such as daytime 
sedation and dependence with continued use. There is a concern about the rationale for and 
extent of benzodiazepine (BZD) use in the elderly. The sedation due to BZD use is a main 
risk factor for falls and other accidents. Impaired cognitive function with continuous use 
appears to be a major side effect. There is a general awareness that BZD use is inappropriate 
in many patients, and therefore discontinuation should be recommended whenever possible. 
Moreover, long-term use of these drugs should be actively discouraged. Although no 
unanimous recommendations concerning the optimal duration of the withdrawal process exist, 
BZDs may easily be withdrawn during a short period in most patients who are habituated to a 
low dose, if an initial phase with dose reduction and psychological support are provided.  
 
INTRODUCTION 
For almost six decades, benzodiazepines have been used in clinical practice. Following their 
introduction into pharmacotherapy these drugs were welcomed because they were a valuable 
substitute for bromides and barbiturates. Due to their clinical efficacy benzodiazepines 
became by far the most frequently prescribed psychotropic drugs in the world
1
.  
Often, benzodiazepines are prescribed on a long-term basis. Frequently, inappropriately large 
doses of benzodiazepines are prescribed with minimal physician follow-up, especially among 
elderly patients. 
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The problems that arise with the use of benzodiazepines in the elderly may be subtle. Thus, 
clinicians, patients, and family members may have difficulty recognizing them or may assume 
that they are psychopathologic changes rather than drug induced effects.   
The acute administration of benzodiazepines is associated with impairments in cognition, 
memory, coordination and balance. The long-term use, even at therapeutic dosages, has been 
associated with tolerance, dependence and in some patients withdrawal effects
2
.  
Knowledge of the adverse effects of benzodiazepine treatment of insomnia and anxiety in the 
elderly can be important for several reasons. First, the elderly have a much higher use of 
hypnotic medications than young individuals with insomnia and anxiety. Second, the elderly 
are at increased risk for toxicity and adverse effects from medication of all sorts. Third, the 
elderly have a greater potential for drug interactions because of concurrent treatment for other 
health problems
3
. 
Since the beginning of the eighties more attention has been paid to the problems arising from 
the widespread use of benzodiazepines. Apart from the risk of abuse and primary dependency, 
there is also the risk of “low-dose dependency”, which is of special importance because of the 
high rate of long-term benzodiazepine treatment
2
. 
Treatment with benzodiazepines typically is initiated during periods of acute stress, medical 
illness, or hospitalisation, or simply when an old person can no longer cope with the daytime 
sequelae of chronic sleep disturbance. Despite the initial intent to limit their use to a short 
period, some people continue using hypnotics for prolonged periods of time. The onset of this 
pattern of prolonged usage is often insidious, with both psychological and physiological 
factors contributing to its maintenance. Some individuals continue using medications because 
of chronic insomnia or anxiety, but other may do so even after their sleep or mood 
disturbance have subsided. Sometimes, prescriptions of hypnotic drugs are renewed without 
adequate evaluations of continued need or sustained efficacy of the medication
4
.  
 
CLINICAL EFFECTS OF BENZODIAZEPINES 
All BZDs are characterized by, in slightly varying degrees, 5 major effects: hypnosedative, 
anxiolytic, anticonvulsant, muscular relaxant and amnesic. In the short term, BZDs may be 
used safely in certain clinical conditions. With long-term use, tolerance, dependence and 
withdrawal effects may prove to be major drawbacks
5, 6
.   
Hypnotic effects. BZDs accelerate sleep onset, decrease nocturnal arousals, and increase total 
sleep time. Nevertheless, they change the normal sleep pattern: light sleep is prolonged, while 
the duration of slow wave sleep and rapid eye movement sleep is reduced. The onset of the 
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first rapid eye movement sleep episode may be delayed
7
. The aberrant sleep profile possibly 
results from unselective depression of both arousal and sleep mechanisms in the brainstem
8, 9
. 
Anxiolytic effects are present in doses that cause minimal sedation, although the hypnotic, 
muscular relaxant and amnesic actions may all provide relief of associated tension and 
insomnia
10
. The effect on anxiety is probably related to suppressive activity in limbic and 
other brain areas involved in anxiogenesis. The main clinical attribute of BZDs prescribed for 
anxiety is the rapid onset of action, usually visible after a single dose. BZDs provide only 
symptomatic treatment for anxiety. Nevertheless they may be indicated in the initial manage-
ment of distressing anxiety, while awaiting enduring clinical effects from more specific non-
drug measures. 
Anticonvulsant effects. BZDs are effective in the treatment of status epilepticus and 
convulsions due to drug poisoning. These drugs can only be used in emergency situations and 
are not appropriate for the extended treatment of epi-lepsy, because of the development of 
tolerance in the majority of patients
11, 12
. 
Muscular relaxant effects of BZDs can sometimes be used in a variety of motor disorders (i.e. 
dystonias and involuntary movements, myoclonus, restless limbs syndrome) and muscle 
spasm associated with pain
13
. 
Amnesic effects. BZDs also cause dose related anterograde amnesia. These amnesic 
properties may be clinically significant, particularly in the elderly and in those with coexisting 
medical problems
14
. 
 
SIDE EFFECTS OF BENZODIAZEPINES 
Although BZDs initially induce and prolong sleep, tolerance develops quickly. Sleep latency 
and duration regress to pre-treatment levels after a few weeks of continued treatment. Sleep 
quality, however, does not improve, since deep NREM sleep and REM sleep stages are 
partially replaced by stage 2 light NREM sleep
15
. Tolerance to the anxiolytic properties of 
BZDs develops more gradually than to the hypnotic effects. Nevertheless, the extended use 
over years helps little to control and may even worsen anxiety. Therefore, BZD use in most 
anxiety states should be restricted to short term (not more than 4 weeks) or intermittent 
courses
16, 17
.  
Rebound insomnia refers to an increase in the original symptom beyond the baseline level 
after withdrawal from BZDs. There have been inconsistent reports of rebound insomnia with 
short-acting BZDs. Population surveys and results from large treatment effectiveness studies 
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show rebound insomnia in 14-20% of patients treated with BZDs, a rate indistinguishable 
from that seen with over-the-counter drugs or placebo
18, 19
.  
BZDs frequently give rise to subjective hangover. Even those BZDs that are quickly 
eliminated may cause the impairment of psychomotor performance and memory the next day. 
The effects depend on type of BZD, dosage and duration of use
20, 21
. 
Residual effects occur mostly with slowly eliminated BZDs, particularly if used in the long 
term and when administered to the elderly
36
. Increased volume of distribution due to a gain in 
body fat, in combination with reduced clearance leads to accumulation of BZDs in the elderly 
and a marked prolongation of t1/2
22
. 
Dependence on BZDs is a psychological or physical need to continue taking these drugs. It 
may be psychological, physical or both. Psychological dependence, also referred to as 
habituation, is characterized by an intermittent or continuous craving for BZDs
23, 24
. Physical 
dependence on BZDs is characterized by a need to take these drugs to prevent the occurrence 
of a withdrawal or abstinence syndrome. The need to continue taking a drug, as reported by 
the patient, is therefore not synonymous with pharmacological dependence. It is part of a 
complex clinical situation, composed by the patient‟s perception, negative conditioning, the 
personality structure, past and current psycho-pathology and also the pattern of chronic BZD 
use
25
. However, if the continuation of a drug is required because it prevents discomfort, this 
can be a sign of psychological dependence on a pharmacological basis
26
.  Sporadically, the 
BZDs may provoke paradoxical stimulation, including excitement, irritability and even 
furious reactions
27
.  
 
SUSCEPTIBILITY OF THE ELDERLY TO BENZODIAZEPINES 
In elderly, BZDs may induce a variety of CNS effects like sedation, lethargy, memory 
problems and deficient coordination, as well as impaired learning and impaired psychomotor 
performance. Utilization of BZDs in hospitalised elderly patients has been related to a higher 
risk of delirium compared with non-users. These drugs are, besides antihypertensive and 
anticholinergic agents, frequently cited as a cause of a dementia-like state
28
. A moderate 
recovery of some cognitive deficits in long-term users, six months after withdrawal from 
BZDs, has been reported
29
. 
The elderly in particular are vulnerable to adverse effects of hypnotic drugs. These patients 
are more sensitive to CNS depression, states of confusion and ataxia that can result in falls 
and fractures
30, 31
. They are as well susceptible to respiratory depression, diminished 
ventilatory response, hypercapnia and increased hypopnoeic episodes during sleep
31
. 
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EPIDEMIOLOGY OF INSOMNIA AND ANXIETY AND BENZO-DIAZEPINE USE IN 
THE ELDERLY 
The prevalence of insomnia increases steadily with age. A literature review mentioned a 
gradually rise from approximately 5% in the age group between 18 and 30 years to a 
prevalence of 40-60% in the subjects aged over 65 years
32
. Prevalence rates of anxiety differ 
between studies and age ranges under observation
33, 34
. It has been estimated that the 
prevalence is about 3% in the general population. Among the patients seen by general 
practitioners a pre-valence of 15-20% has been reported
33, 34
. Most studies in regard to both 
disorders only report data for individuals over 65 years as one group. Individuals over 65 
receive 30% of all prescriptions for BZDs and non-BZD minor sedatives. One-year exposure 
to BZD use for the elderly averages 32% (range 9-54%)
35
. Current prevalence of BZD use in 
the institutional setting varies between 11 and 42%
35-37
. In comparison, current prevalence of 
BZD use in the community setting among the elderly varies between 10 and 37%
35, 38
. A 
prototype of a long-term user is an aged widowed female with various health problems and a 
moderate psychiatric disorder
23,39
. Widespread BZD use is particularly common in nursing 
homes. Sleep disturbances and changes in sleep-wake cycle are frequent in patients with 
Alzheimer‟s dementia. This clinical picture has also been referred to as “the sundown 
syndrome”40--42. The changes in sleep behaviour include spending more time in bed, sleeping 
less than usual, trouble getting the patient out of bed, a day/night reversal of sleep pattern and 
nightmares upon awakening
43
. 
 
Rationale for prescription 
It is essential that the practitioner develops a treatment plan when utilizing benzodiazepines to 
treat older patients. There is a growing agreement with the view that most patients currently 
taking benzodiazepines should discontinue them whenever possible
44
. If physical dependence 
exists without other adverse effects, the clinician and the patient can decide whether to 
detoxify from benzodiazepines and attempt alternative treatments. If benzodiazepine may be a 
factor in exacerbating the patient‟s problem, withdrawal is preferred, and observation of 
benzodiazepine therapy should be continued for at least 6 weeks to allow the possible effects 
of withdrawal or rebound to be evaluated. It has been shown that there is a significant 
improvement of memory and cognitive functioning following discontinuance, not necessary 
associated  with  increase in anxiety, agitation or sleeplessness
44
. Before initiating 
discontinuation of hypnotics, it is essential to evaluate the patient‟s readiness and motivation 
concerning the undertaking of this program. Discontinuation of a hypnotic drug is more likely 
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to be successful if motivation is intrinsic, rather than extrinsic. Providing information about 
the risks ( i.e. memory impairment, falls and hip fractures) may be useful, but ultimately the 
patient should make the decision on his or her own. Some patients are apprehensive about 
withdrawal symptoms and rebound insomnia. Information about the tapering schedule and 
about the transient nature of most withdrawal symptoms should alleviate some of those 
concerns. Other patients may have very low self-confidence regarding their ability to 
discontinue medication. They should be encouraged to view this program as an opportunity to 
achieve greater self-control over their sleep and their life in general. 
 
Guidelines for withdrawal 
There is a general agreement on the notion that most patients who take BZDs regularly should 
try to discontinue treatment
45, 46
. Many patients who have taken BZDs for years can have 
these drugs withdrawn successfully. Older women with anxious symptoms and personality 
disturbance respond less successfully to withdrawing
23
.  
The factors presumed to affect withdrawal are personality profile, dose and half-life of BZDs, 
duration of treatment and mode of withdrawal
23, 47
. In contrast, there are reports sharing the 
observation that with the exception of age, withdrawal outcome is not related to any particular 
variable
46
. Withdrawal symptoms, if any, occur most often after 3 months of habitual use. 
They may include anxiety, restlessness, sleep disturbance, headache, muscle cramps, nausea, 
delirium or convulsions.  
The treatment of BZD withdrawal includes suitable psychological support together with a 
gradual dosage tapering. In most of the cases, sleep symptoms progressively improve after 
withdrawal. It has been demonstrated that the elderly tolerate withdrawal as well as, if not 
better than young individuals
48
.  
There are no unanimous recommendations in the literature regarding the optimal duration of 
the withdrawal process. Hence, a variable withdrawal period ranging from 2 to 12 weeks may 
be allowed. The size of the stepwise lowering in dosage that should be utilized is arguable as 
well. Certain investigators use a fixed tapering schedule, while others claim that the reduction 
rate should be titrated against the patient‟s withdrawal symptoms49. Only five studies have 
evaluated withdrawal severity and outcomes in an elderly group
29, 49, 50, 48, 43
. Table 1 
summarizes these studies.  
Recently Petrovic et al. showed that a short-term BZD withdrawal program is possible in the 
hospital setting
49
. Most geriatric patients who are habituated to a low dose of BZDs may wean 
during a short period, if an initial phase with dose reduction and psychological support is 
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included in the withdrawal programme. Two-thirds of chronic elderly users can thus 
successfully be withdrawn from BZDs by a single step of dose reduction, maintained during 1 
week
49, 50
. The authors conclude that a faster taper should be encouraged, as it may fit in a 
short-term admission to the ward. Withdrawal symptoms, if any, will not pass unrecognised 
and may be sufficiently treated. The general practitioners should be involved in the decision 
to stop the treatment with BZDs, in addition to the follow-up after discharge from the 
hospital. 
The study of Salzman regarding BZD discontinuation in the elderly showed no increase in 
anxiety, agitation and sleep disturbances in those who discontinued BZDs as compared with 
baseline levels. In addition, measures of memory and cognitive function revealed an 
important improvement following disconti-nuation
44
. Several lines of evidence thus point to 
the feasibility and advantages of eliminating BZDs from treatment regimens in elderly. The 
uneventful withdrawal that is obtained in many cases reflects the fact that the use of BZDs in 
the elderly is more habitual and sometimes based on an indulgence of the treating physician to 
meet the request of prescribing “something for sleep or nerves”.  
These findings lend support to the hypothesis that a short-term benzodiazepine withdrawal 
programme is feasible in the hospital setting. Most geriatric patients who are habituated to a 
low-dose benzodiazepine treatment may wean in one or two weeks, provided that an initial 
phase with dose reduction and psychological support is included in the withdrawal 
programme. A faster taper is advantageous, as it may well fit in a short-term admission to the 
ward. Withdrawal symptoms, if any, will not go unnoticed and may be adequately treated. 
Psychological rather than physical dependence proved to be the main reason for relapse in our 
patients group. To cope with this problem remains a considerable challenge in programmes 
aimed at weaning from psychotropic drugs.  
A profound discriminatory history should identify a real cause of insomnia and/or anxiety 
among diverse somatic, psychological and situational factors in order to line up a problem 
oriented treatment strategy. 
As to future perspective, non-pharmacological programs should be given a priority in respect 
of avoiding the use of hypnotic drugs. Psychological support and follow-up of the patient 
make herein an important task for caregivers. Patients already using benzodiazepines should 
be advised to discontinue these medications. Before initiation of a withdrawal programme, 
caregivers should inform the patient that withdrawal from benzodiazepines in combination 
with psychological support, could consolidate sleep and enhance the restorative value of 
sleep, but will not change the depth and duration of sleep. Participants in a withdrawal 
 8 
 
 
programme should have ample access to conversational assistance from the psychologist, 
nurse or physician on the ward. They should be encouraged to continue, though a formal 
request for cessation of the programme should not be declined. Caregivers should combine 
this ancillary care with non-pharmacological interventions.  
Finally, the role of the general practitioner in the non-pharmacological approach of insomnia 
and anxiety must not be neglected. The primary care physician may intervene at different care 
providing levels to improve psychological and social support of elderly patients. Such 
interventions may obviate the need for symptomatic sedation. Herewith, it is important that 
the general practitioner and hospital caregivers should respect the same approach. 
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Table 1.  Benzodiazepine withdrawal studies in geriatric patients  
Study N Age Population Study 
design 
Description 
of taper 
BZD 
dose 
(mg)* 
Outcome 
measure 
% 
Completed 
 
Schweizer 
et al 
(1989) 
41 
19 
22 
 
66.4 
34.4 
Outpatients Open- 
label 
gradual 
taper 
 
25% 
reduction per 
week 
 
16.4 
16.6 
 
Withdrawal  
symptoms 
BZD 
plasma 
levels 
50%  BZD 
free at 7 
weeks 
Salzman 
et al 
(1992) 
25 86 Nursing 
home 
Single- 
blind 
gradual 
taper 
2 weeks of 
gradual taper 
then 
discontinued 
 
10 Cognition, 
sleep, 
mood 
60% BZD 
free at 12 
months 
Habraken 
et al 
(1997) 
55 84 Nursing 
home 
Randomised, 
double- 
blind, 
gradual 
taper 
Reduction by 
25% for 3 
weeks, then 
by 12.5% for 
2 weeks, then 
placebo for 
12 months 
Control 
lorazepam for 
12 months 
 
10 Daily 
function, 
sleep 
quality 
63% BZD 
free at 6 
weeks 
Petrovic 
et al 
(1999) 
49 81.4 Geriatric 
medicine 
inpatients 
Randomised, 
single 
blind 
Brief 
educational 
intervention 
Replacement 
with either 
lormetazepam 
10 Sleep 
quality 
67.9% 
BZD 
free at 6 
weeks 
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or tradozone 
for 1 week, 
then 
discontinue 
all sedatives 
 
Petrovic 
et al 
(2002) 
40 81.5 Geriatric 
medicine 
inpatients 
Randomised, 
double 
blind 
Brief 
educational 
intervention 
Replacement 
with either 
lormetazepam 
or placebo  
for 1 week, 
then 
discontinue 
all sedatives 
 
12.5 Sleep 
quality, 
withdrawal 
symptoms 
65% BZD 
free at 4 
weeks, 
30% 
BZD free 
at 
12 months 
BZD = benzodiazepine. * Mean daily dose in diazepam equivalents. 
 
 
